Linda Berná

Linda Berná

Auto-generated profile, based on publicly available information

Linda Berná

Institute of Inherited Metabolic Diseases, Charles University, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2010 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
HPHelena Poupětová
Helena Poupětová
JLJana Ledvinová
Jana Ledvinová
LBLinda Berná
Linda Berná
LDLenka Dvořáková
Lenka Dvořáková
VKViktor Kožich
Viktor Kožich
MEMilan Elleder
Milan Elleder
The aim of this retrospective study was to determine the prevalence of lysosomal storage disorders (LSDs) in the Czech Republic. The data on cases diagnosed between 1975 and 2008 were collected and analyzed. The overall prevalence of LSDs in the Czech population (12.25 per 100,000) is comparable to that reported for the countries with well‐established and advanced diagnostics of LSDs such as the Netherlands (14 per 100,000), Australia (12.9 per 100,000) and Italy (12.1 per 100,000). Relatively higher prevalence of LSDs was reported in the north of Portugal (25 per 100,000). Thirty‐four different LSDs were diagnosed in a total of 478 individuals. Gaucher disease was the most frequent LSD with a birth prevalence of 1.13 per 100,000 births. The most frequent LSD groups were lipidoses, mucopolysaccharidoses, and neuronal ceroid lipofuscinoses, with combined prevalences of 5.0, 3.72, and 2.29 per 100,000 live births, respectively. Glycoproteinoses (0.57 per 100,000 live births), glycogenosis type II (0.37), and mucolipidoses (0.31) rarely occur in the Czech population, and a range of other LSDs have not been detected at all over the past three decades. Knowledge of the birth prevalence and carrier frequency of particular disorders is important in genetic counselling for calculation of the risk for the disorder in the other members of affected families. Earlier diagnosis of these disorders will permit timely intervention and may also result in lowering of the number of newborns with LSDs.

24 March 2009 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
LKLadislav Kuchař
Ladislav Kuchař
JLJana Ledvinová
Jana Ledvinová
MHMartin Hřebíček
Martin Hřebíček
HMHelena Myšková
Helena Myšková
LDLenka Dvořáková
Lenka Dvořáková
KHKlaus Harzer
Klaus Harzer
Prosaposin deficiency (pSap‐d) and saposin B deficiency (SapB‐d) are both lipid storage disorders caused by mutations in the PSAP gene that codes for the 65–70 kDa prosaposin protein, which is the precursor for four sphingolipid activator proteins, saposins A–D. We report on two new patients with PSAP gene defects; one, with pSap‐d, who had a severe neurovisceral dystrophy and died as a neonate, and the other with SapB‐d, who presented with a metachromatic leukodystrophy‐like disorder but had normal arylsulfatase activity. Screening for urinary sphingolipids was crucial to the diagnosis of both patients, with electrospray ionization tandem mass spectrometry also providing quantification. The pSap‐d patient is the first case with this condition where urinary sphingolipids have been investigated. Multiple sphingolipids were elevated, with globotriaosylceramide showing the greatest increase. Both patients had novel mutations in the PSAP gene. The pSap‐d patient was homozygous for a splice‐acceptor site mutation two bases upstream of exon 10. This mutation led to a premature stop codon and yielded low levels of transcript. The SapB‐d patient was a compound heterozygote with a splice‐acceptor site variant exclusively affecting the SapB domain on one allele, and a 2 bp deletion leading to a null, that is, pSap‐d mutation, on the other allele. Phenotypically, pSap‐d is a relatively uniform disease of the neonate, whereas SapB‐d is heterogeneous with a spectrum similar to that in metachromatic leukodystrophy. The possible existence of genotypes and phenotypes intermediate between those of pSap‐d and the single saposin deficiencies is speculated.

20 March 2008 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
JKJana Keslová-Veselíková
Jana Keslová-Veselíková
HHHelena Hůlková
Helena Hůlková
RDRobert Dobrovolný
Robert Dobrovolný
BABefekadu Asfaw
Befekadu Asfaw
HPHelena Poupětová
Helena Poupětová
MEMilan Elleder
Milan Elleder
The function and intracellular delivery of enzyme therapeutics for Fabry disease were studied in cultured fibroblasts and in the biopsied tissues of two male patients to show diversity of affected cells in response to treatment. In the mutant fibroblasts cultures, the final cellular level of endocytosed recombinant α-galactosidases A (agalsidases, FabrazymeTM, and ReplagalTM) exceeded, by several fold, the amount in control fibroblasts and led to efficient direct intra-lysosomal hydrolysis of (3H)Gb3Cer. In contrast, in the samples from the heart and some other tissues biopsied after several months of enzyme replacement therapy (ERT) with FabrazymeTM, only the endothelial cells were free of storage. Persistent Gb3Cer storage was found in cardiocytes (accompanied by increase of lipopigment), smooth muscle cells, fibroblasts, sweat glands, and skeletal muscle. Immunohistochemistry of cardiocytes demonstrated, for the first time, the presence of a considerable amount of the active enzyme in intimate contact with the storage compartment. Factors responsible for the limited ERT effectiveness are discussed, namely post-mitotic status of storage cells preventing their replacement by enzyme supplied precursors, modification of the lysosomal system by longstanding storage, and possible relative lack of Sap B. These observations support the strategy of early treatment for prevention of lysosomal storage.

24 April 2009 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
AVAlzbeta Vazna
Alzbeta Vazna
CBClare Beesley
Clare Beesley
LBLinda Berna
Linda Berna
LSLarisa Stolnaja
Larisa Stolnaja
HMHelena Myskova
Helena Myskova
LDLenka Dvorakova
Lenka Dvorakova
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder that is caused by a deficiency of the enzyme α‐L‐iduronidase (IDUA). Of the 21 Czech and Slovak patients who have been diagnosed with MPS I in the last 30 years, 16 have a severe clinical presentation (Hurler syndrome), 2 less severe manifestations (Scheie syndrome), and 3 an intermediate severity (Hurler/Scheie phenotype). Mutation analysis was performed in 20 MPS I patients and 39 mutant alleles were identified. There was a high prevalence of the null mutations p.W402X (12 alleles) and p.Q70X (7 alleles) in this cohort. Four of the 13 different mutations were novel: p.V620F (3 alleles), p.W626X (1 allele), c.1727 + 2T > G (1 allele) and c.1918_1927del (2 alleles). The pathogenicity of the novel mutations was verified by transient expression studies in Chinese hamster ovary cells. Seven haplotypes were observed in the patient alleles using 13 intragenic polymorphisms. One of the two haplotypes associated with the mutation p.Q70X was not found in any of the controls. Haplotype analysis showed, that mutations p.Q70X, p.V620F, and p.D315Y probably have more than one ancestor. Missense mutations localized predominantly in the hydrophobic core of the enzyme are associated with the severe phenotype, whereas missense mutations localized to the surface of the enzyme are usually associated with the attenuated phenotypes. Mutations in the 130 C‐terminal amino acids lead to clinical manifestations, which indicates a functional importance of the C‐terminus of the IDUA protein.

1 May 1999 in Analytical Biochemistry
Verified
Journal Article
Closed access
LBLinda Berná
Linda Berná
BABefekadu Asfaw
Befekadu Asfaw
ECErnst Conzelmann
Ernst Conzelmann
BČBohuslav Černý
Bohuslav Černý
JLJana Ledvinová
Jana Ledvinová

1 November 2005 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
Agnieszka ŁugowskaAgnieszka Ługowska
Agnieszka Ługowska
Olga AmaralOlga Amaral
Olga Amaral
Johannes BergerJohannes Berger
Johannes Berger
LBLinda Berna
Linda Berna
NBNils U. Bosshard
Nils U. Bosshard
BCBarbara Czartoryska
Barbara Czartoryska